FILTER
FILTERED INTERVIEW RESULTS
Șirin Deha
FOUNDER & GM ERA PHARMA SOLUTIONS
ERA Pharma Solutions is a contract research organization (CRO) established in 2010 to provide drug discovery, development and lifecycle management services for the pharmaceutical industry.
James Sapirstein
PRESIDENT AND CEO, AZURRX BIOPHARMA
AzurRx BioPharma is a development stage biopharmaceutical company focused on the development of recombinant proteins for the treatment of gastrointestinal diseases and microbiome related conditions.
Neha Ramani
PARTNER, LEXORBIS
Lex Orbis provides IP and legal services to the life science industry in India and beyond and comments on the exciting evolution of technology and research in India.
Dr. Trevor P. Castor
PRESIDENT & CEO, APHIOS
Aphios’ vision is to develop biotechnology products for improving health and treating chronic diseases in an environmentally sustainable manner.
Jay Shukla
PRESIDENT AND CEO, NIVAGEN PHARMACEUTICALS
Nivagen is engaged in the development, acquisition and sales of generic prescription drugs and OTC products for the North American market.
Doug Giordano
SENIOR VP OF BUSINESS DEVELOPMENT, PFIZER
Pfizer outlines its plans to build its pipeline through partnerships as the company increasingly focuses on new science.
Hasan Ulusoy
CHAIRMAN, NOBEL İLAÇ
Nobel is an internationally active pharmaceutical company founded in 1964, representing the Turkish brand in a wide range of geographies.
Michael Gladstone
PRINCIPAL, ATLAS VENTURE
Atlas Venture is an early-stage venture capital firm that invests in life sciences startup companies in the US.
Akshay Charegaonkar
DIRECTOR, ANCHROM ENTERPRISES
Anchrom Enterprises offers high-end analytical solutions together with technical expertise, acting as the exclusive distributors of Camag HPTLC.
Bhagyesh Shah
MANAGING DIRECTOR, UNISON PHARMACEUTICALS
Unison Pharmaceuticals Private Limited was established in 1981, with a vision of providing quality affordable medicines across India and is now ready to go global.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
